Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 12;24(1):62.
doi: 10.1186/s12885-024-11818-5.

Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study

Xiaoling Huang #  1 , Ying Wang #  1 , Zhenyu Huang  2 , Xuzheng Chen  3   4 , Qiuyan Lin  1 , Haobo Huang  5 , Liping Fan  6
Affiliations

Low serum apolipoprotein A1 level predicts poor prognosis of patients with diffuse large B-cell lymphoma in the real world: a retrospective study

Xiaoling Huang et al. BMC Cancer. .

Abstract

Background: Apolipoprotein A1 (ApoA1) is a member of the apolipoprotein family with diverse functions. It is associated with the pathogenesis and prognosis of several types of tumors. However, the role of serum apolipoprotein A1 (ApoA1) in the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. This study aimed to elucidate its influence on clinical outcomes in patients with DLBCL.

Methods: We retrospectively analyzed a cohort of 1583 consecutive DLBCL patients admitted to the Fujian Medical University Union Hospital between January 2011 and December 2021. 949 newly diagnosed DLBCL patients who met the inclusion criteria were enrolled for statistical analysis. Receiver operating characteristic curve analysis was performed to determine the optimal cut-off value for serum ApoA1 levels for prognostic prediction among patients with DLBCL. The correlations between serum ApoA1 levels and clinical and laboratory parameters were analyzed. Prognostic significance was analyzed using univariate and multivariate Cox proportional hazards models.

Results: Newly diagnosed patients with DLBCL demonstrated low serum ApoA1 levels (< 0.925 g/L), had more B symptoms, higher levels of serum lactate dehydrogenase (LDH) (>upper limit of normal), poorer performance status (Eastern Cooperative Oncology Group score of 2-4), higher percentage of advanced stage and non-germinal center B-cell (non-GCB) subtype, more cases of > 1 extranodal site, higher International Prognostic Index (IPI) score (3-5), and higher incidence of relapse or refractory diseases compared with those with high serum ApoA1 levels (≥ 0.925 g/L). Low serum ApoA1 levels were an independent adverse prognostic factor for overall survival (OS) but not progression-free survival (PFS).

Conclusions: Low serum ApoA1 levels were associated with poor treatment response and inferior survival in newly diagnosed patients with DLBCL.

Keywords: Apolipoprotein A1; DLBCL; Prognostic factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart showing the retrospective screening process for patients with DLBCL
Fig. 2
Fig. 2
Serum ApoA1 levels in newly diagnosed patients with DLBCL and healthy individuals
Fig. 3
Fig. 3
ROC analysis of pretreatment serum ApoA1 levels (AUC = 0.661; 95% CI: 0.614–0.707, P < 0.001)
Fig. 4
Fig. 4
OS and PFS of newly diagnosed DLBCL patients according to pretreatment serum ApoA1 levels. A: OS; B: PFS
See this image and copyright information in PMC

References

    1. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620. - DOI - PMC - PubMed
    1. Shi Y, Han Y, Yang J, Liu P, He X, Zhang C, Zhou S, Zhou L, Qin Y, Song Y, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res. 2019;31(1):152–161. doi: 10.21147/j.issn.1000-9604.2019.01.10. - DOI - PMC - PubMed
    1. Liu P, Han Y, Jiang SY, He XH, Qin Y, Gui L, Zhou SY, Zhou LQ, Yang JL, Yang S, et al. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma. Chin Med J (Engl) 2019;132(15):1807–1814. doi: 10.1097/CM9.0000000000000354. - DOI - PMC - PubMed
    1. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner-Johnston ND, Karmali R, et al. Outcomes in patients with aggressive B-cell non-hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020;126(2):293–303. doi: 10.1002/cncr.32526. - DOI - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed

LinkOut - more resources